Surface modification and characterization of agglomerated metal oxide particles
2013
0 görüntülenme
0 i̇ndirme
Danışman: Prof. Dr. Mustafa Çulha
Özet (EN)
Metal Oxide nanomaterials (MONMs) attracted enormous attention due to their unique physicochemical properties and are used in many applications including drugs, paints, biomedical devices and development of novel materials. The surface modification of namomaterials (NMs) is an important step to alter their behavior to further benefit from their unique properties in variety of applications. However, the main problem with them in order to work efficiently is their inefficient dispersion in aqueous environments. In this study, we aimed to understand the surface properties of these materials as we attempt to alter the surface chemistry. Surface coating of the NMs with oligonucleotides, carbohydrates and treatment with hydrogen peroxide (H2O2) help them to stabilize as mono-disperse particles in their colloidal suspensions. The characterization of modified MONMs was performed with Raman Spectroscopy, FTIR Spectroscopy and Dynamic Light Scattering (DLS).
Yazar
Sinan Sabuncu
Bu Yayına Nasıl Atıf Yapılır
Sinan Sabuncu (Master Thesis). Surface modification and characterization of agglomerated metal oxide particles, 2013, Yeditepe University.
Anahtar Kelimeler
Lisans
Tüm Hakları Saklıdır
Bu eser belirtilen lisans koşulları altında paylaşılmaktadır.
Yeditepe University tezlerinden daha fazlası
- Studies on cyclodextrin complexation of a poorly water soluble anti-hyperlipidemic drug, tablet formulation and characterization(2021)
- Washington ambassadors in Turkish-US relations (1927-1960)(2023)
- Metamorphosis of female voices: A study of the violation of women in Greek and Roman mythology and feminist rewritings reclaiming the narrative(2022)
- Knowledge distillation with foundation models for image segmentation(2023)
- The relationship between machiavelism, grandiose and vulnerable narcissism, and loneliness among white collar workers(2023)
- Evaluation of drug-drug interaction checkers along clinically relevant adverse drug events in oncology and hematology pediatric patients(2023)